Last reviewed · How we verify

ADEFOVIR — Competitive Intelligence Brief

ADEFOVIR (ADEFOVIR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

discontinued DNA polymerase subunit gamma-1, Capsid protein, Protein P Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ADEFOVIR (ADEFOVIR). Adefovir is an antiviral medication used to treat chronic hepatitis B in adults and adolescents, with common side effects including fatigue, headache, and stomach pain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADEFOVIR TARGET ADEFOVIR discontinued DNA polymerase subunit gamma-1, Capsid protein, Protein P
Hepsera Hepsera Gilead Sciences marketed DNA polymerase subunit gamma-1, Capsid protein, Protein P

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADEFOVIR — Competitive Intelligence Brief. https://druglandscape.com/ci/adefovir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: